NCT03647358 Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
| NCT ID | NCT03647358 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Thyroid Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2018-08-21 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2018-08-21 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. However, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.
Eligibility Criteria
Inclusion Criteria: * Adults with thyroid carcinoma confirmed by pathology. * Adult thyroid carcinoma patients who have undergone total thyroidectomy * Adult thyroid carcinoma patients have metastatic disease or suspicion for metastatic disease, or are under a protocol intended to explore re-induction therapy for 131I uptake, and are about to undergo Thyrogen-assisted dosimetry, unless Thyrogen-assisted dosimetry is not required per standard of care. * The patient and physician are planning to administer 131I for therapy if persistent radioiodine-avid metastases are present. * All subjects must have measurable disease, documented within the previous six months by ultrasonography (US), MRI, FDG PET/CT, or CT scanning. Exclusion Criteria: * Age less than 18 years. * Patients who are pregnant.
Contact & Investigator
Ravinder Grewal, MD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT03647358 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thyroid Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03647358 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT03647358 currently recruiting?
Yes, NCT03647358 is actively recruiting participants. Contact the research team at grewalr@mskcc.org for enrollment information.
Where is the NCT03647358 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT03647358 clinical trial?
NCT03647358 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Ravinder Grewal, MD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 60 participants.